Evidence map›Paper›PMID 37100956›Full record

ReviewAAPS PharmSciTech2023

Topical Nanotherapeutics for Treating MRSA-Associated Skin and Soft Tissue Infection (SSTIs).

Sriravali Karnam, Anil B Jindal, Charu Agnihotri, Bhim Pratap Singh, Atish T Paul

Abstract readReview
PubMed Publisher
In one paragraph

Review in AAPS PharmSciTech, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sriravali KarnamDepartment of Pharmacy, Birla Institute of Technology and Sciences Pilani (BITS-Pilani), Pilani Campus, Vidyavihar, Pilani, 333031, Rajasthan, India.
Anil B JindalDepartment of Pharmacy, Birla Institute of Technology and Sciences Pilani (BITS-Pilani), Pilani Campus, Vidyavihar, Pilani, 333031, Rajasthan, India.
Charu AgnihotriDepartment of Agriculture & Environmental Sciences (AES), Technology Entrepreneurship & Management (NIFTEM), National Institute of Food, Sonipat, 131028, Haryana, India.
Bhim Pratap SinghDepartment of Agriculture & Environmental Sciences (AES), Technology Entrepreneurship & Management (NIFTEM), National Institute of Food, Sonipat, 131028, Haryana, India. bpsingh@niftem.ac.in.
Atish T PaulDepartment of Pharmacy, Birla Institute of Technology and Sciences Pilani (BITS-Pilani), Pilani Campus, Vidyavihar, Pilani, 333031, Rajasthan, India. atish.paul@pilani.bits-pilani.ac.in.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The emergence of methicillin-resistant Staphylococcus aureus (MRSA) imposes a major challenge for the treatment of infectious diseases with existing antibiotics. MRSA associated with superficial skin and soft tissue infections (SSTIs) is one of them, affecting the skin's superficial layers, and it includes impetigo, folliculitis, cellulitis, furuncles, abscesses, surgical site infections, etc. The efficient care of superficial SSTIs caused by MRSA necessitates local administration of antibiotics, because oral antibiotics does not produce the required concentration at the local site. The topical administration of nanocarriers has been emerging in the area of drug delivery due to its advantages over conventional topical formulation. It enhances the solubility and permeation of the antibiotics into deeper layer of the skin. Apart from this, antibiotic resistance is something that needs to be combated on multiple fronts, and antibiotics encapsulated in nanocarriers help to do so by increasing the therapeutic efficacy in a number of different ways. The current review provides an overview of the resistance mechanism in S. aureus as well as various nanocarriers reported for the effective management of MRSA-associated superficial SSTIs.

Indexed as

Community-Acquired InfectionsMethicillin-Resistant Staphylococcus aureusSoft Tissue InfectionsStaphylococcal InfectionsAnti-Bacterial AgentsHumansStaphylococcus aureusAnti-Bacterial Agentsmetallic nanoparticlesMRSAnanocarriersresistanceSSTIsStaphylococcus aureustopical antibiotics

Identifiers

PMID37100956

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.